JPH08508721A - 超常磁性粒子、その製法及びその用途 - Google Patents

超常磁性粒子、その製法及びその用途

Info

Publication number
JPH08508721A
JPH08508721A JP6520523A JP52052394A JPH08508721A JP H08508721 A JPH08508721 A JP H08508721A JP 6520523 A JP6520523 A JP 6520523A JP 52052394 A JP52052394 A JP 52052394A JP H08508721 A JPH08508721 A JP H08508721A
Authority
JP
Japan
Prior art keywords
superparamagnetic
particles
group
magnetic
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6520523A
Other languages
English (en)
Japanese (ja)
Inventor
ピルグリム，ハーバート
Original Assignee
シリカゲル ゲス．エム．ビー．エイチ
ピルグリム，ハーバート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4309333A external-priority patent/DE4309333A1/de
Application filed by シリカゲル ゲス．エム．ビー．エイチ, ピルグリム，ハーバート filed Critical シリカゲル ゲス．エム．ビー．エイチ
Publication of JPH08508721A publication Critical patent/JPH08508721A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1887—Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/01—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials
    • H01F1/03—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity
    • H01F1/12—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials
    • H01F1/34—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
    • H01F1/36—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites in the form of particles
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/44—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of magnetic liquids, e.g. ferrofluids
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/44—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of magnetic liquids, e.g. ferrofluids
    • H01F1/445—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of magnetic liquids, e.g. ferrofluids the magnetic component being a compound, e.g. Fe3O4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/84—Polymer coating, e.g. gelatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/86—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids the coating being pre-functionalised for attaching immunoreagents, e.g. aminodextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/281—Means for the use of in vitro contrast agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Power Engineering (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
JP6520523A 1993-03-17 1994-03-17 超常磁性粒子、その製法及びその用途 Pending JPH08508721A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4309333A DE4309333A1 (de) 1993-03-17 1993-03-17 Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben
DE4407338A DE4407338A1 (de) 1993-03-17 1994-03-02 Superparamagnetische Teilchen und deren Verwendung
DE4407338.0 1994-03-02
DE4309333.7 1994-03-02
PCT/DE1994/000314 WO1994021240A2 (de) 1993-03-17 1994-03-17 Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben

Publications (1)

Publication Number Publication Date
JPH08508721A true JPH08508721A (ja) 1996-09-17

Family

ID=25924241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6520523A Pending JPH08508721A (ja) 1993-03-17 1994-03-17 超常磁性粒子、その製法及びその用途

Country Status (6)

Country Link
US (1) US5916539A (zh-CN)
EP (1) EP0689430B1 (zh-CN)
JP (1) JPH08508721A (zh-CN)
AT (1) ATE156706T1 (zh-CN)
DE (1) DE59403734D1 (zh-CN)
WO (1) WO1994021240A2 (zh-CN)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507197A (ja) * 1996-03-18 2000-06-13 ピルグリム，ヘルベルト Ｒ▲下１▼緩和性を増加した超常磁性体粒子、前記粒子の製造方法およびその使用
JP2005511335A (ja) * 2001-04-13 2005-04-28 コーネル・リサーチ・ファンデーション・インコーポレイテッド 超常磁性ナノ構造材料
JP2006502572A (ja) * 2002-10-09 2006-01-19 フェロファーマ ゲーエムベーハー フォルシュングスラボア 安定化超常磁性粒子
JP2006042621A (ja) * 2004-07-30 2006-02-16 Canon Inc 磁性粒子集合体およびそれを用いた標的核酸の抽出装置および抽出方法
WO2006068294A1 (ja) * 2004-12-24 2006-06-29 Japan Science And Technology Agency 造影剤
JP2009531296A (ja) * 2006-02-24 2009-09-03 エイティージェン カンパニー リミテッド 造影剤、知能型造影剤、同時診断及び治療のための薬物伝達体及び／又はタンパク質分離用磁性ナノ複合体
JP2010516782A (ja) * 2007-01-26 2010-05-20 ゼネラル・エレクトリック・カンパニイ Ｘ線／コンピュータ断層撮影用のナノ粒子系造影剤及びその製造方法
US9149545B2 (en) 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
WO1997016474A1 (en) * 1995-11-01 1997-05-09 Bracco Research S.A. Targeted magnetically labeled molecular marker systems for the nmr imaging
CN1212629A (zh) 1996-01-10 1999-03-31 耐克麦德英梅金公司 造影剂
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
DE19600744A1 (de) * 1996-01-11 1997-07-17 Werner Alois Prof Dipl Kaiser Magnetische Substanz zur lokalen hyperthermischen Behandlung vorwiegend kleiner Tumore
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
DE19622628A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilisierung von Metallkonjugaten
JP3662347B2 (ja) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 医療用粉体
AU727764B2 (en) * 1996-08-05 2000-12-21 Schering Aktiengesellschaft Process for the production of contrast media for magnetic resonance tomography
US20060003163A1 (en) * 1996-11-16 2006-01-05 Nanomagnetics Limited Magnetic fluid
US6815063B1 (en) 1996-11-16 2004-11-09 Nanomagnetics, Ltd. Magnetic fluid
US6986942B1 (en) 1996-11-16 2006-01-17 Nanomagnetics Limited Microwave absorbing structure
US6713173B2 (en) 1996-11-16 2004-03-30 Nanomagnetics Limited Magnetizable device
GB2319253A (en) 1996-11-16 1998-05-20 Eric Leigh Mayes Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles
US6689485B2 (en) * 1997-01-17 2004-02-10 The Penn State Research Foundation Powerful reductant for decontamination of groundwater and surface streams
GB9715770D0 (en) * 1997-07-25 1997-10-01 Nycomed Imaging As Process
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6821456B2 (en) * 1998-09-22 2004-11-23 Albemarle Corporation Granular polymer additives and their preparation
US6056898A (en) * 1998-09-22 2000-05-02 Albemarle Corporation Low dust balanced hardness antioxidant pellets and process for the production of same
US5973138A (en) * 1998-10-30 1999-10-26 Becton Dickinson And Company Method for purification and manipulation of nucleic acids using paramagnetic particles
US6908955B2 (en) * 1999-07-09 2005-06-21 Construction Research & Technology Gmbh Oligomeric dispersant
SE9903183D0 (sv) * 1999-09-08 1999-09-08 Europ I Of Science Ab Selektivt bindande och magnetiskt påverkbara nanopartiklar för medicinskt bruk
GB9921579D0 (zh-CN) * 1999-09-13 1999-11-17 Nycomed Imaging As
RU2166751C1 (ru) * 2000-03-09 2001-05-10 Никитин Петр Иванович Способ анализа смеси биологических и/или химических компонентов с использованием магнитных частиц и устройство для его осуществления
DE10016559A1 (de) * 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
DE10017489A1 (de) * 2000-04-07 2001-10-11 Emtec Magnetics Gmbh Magnetisches Aufzeichnungsmedium
WO2002000870A2 (en) * 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
US20020086842A1 (en) * 2000-06-26 2002-07-04 Christian Plank Method for transfecting cells using a magnetic field
DE10033583A1 (de) * 2000-07-11 2002-01-24 Bayer Ag Superparamagnetische Perlpolymerisate
US6515052B2 (en) * 2001-02-23 2003-02-04 Albemarle Corporation Granular polymer additives and their preparation
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7018849B2 (en) * 2002-01-15 2006-03-28 Piasio Roger N Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
DE10205332B4 (de) * 2002-02-06 2004-02-12 Berlin Heart Ag Verfahren zur Herstellung von magnetischen Nanoteilchen
AU2003225587A1 (en) * 2002-02-21 2003-09-09 University Of Oregon Cross-linkable phosphonate-containing supramolecular complexes and their use for delivery of therapeutic and diagnostic agents
US7054118B2 (en) * 2002-03-28 2006-05-30 Nve Corporation Superparamagnetic field sensing devices
DE10222481A1 (de) * 2002-05-22 2003-12-04 Eucro Europe Contract Res Gmbh Kontrastmittel für die Verwendung in bildgebenden Verfahren
DE60316748T2 (de) * 2002-06-27 2008-02-07 Toyo Boseki K.K. Magnetischer Träger für biologische Substanzen, Verfahren zur seiner Produktion und seiner Verwendung zur Isolierung dieser biologischen Substanzen
CA2549994A1 (en) * 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US7601491B2 (en) * 2003-02-06 2009-10-13 Becton, Dickinson And Company Pretreatment method for extraction of nucleic acid from biological samples and kits therefor
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
US20040157219A1 (en) * 2003-02-06 2004-08-12 Jianrong Lou Chemical treatment of biological samples for nucleic acid extraction and kits therefor
US8532735B2 (en) * 2003-04-15 2013-09-10 Koninklijke Philips N.V. Device and method for examination and use of an electrical field in an object under examination containing magnetic particles
US7635734B2 (en) * 2004-02-17 2009-12-22 The Children's Hospital Of Philadelphia Photochemical activation of surfaces for attaching biomaterial
US9694103B2 (en) 2003-04-16 2017-07-04 The Children's Hospital Of Philadelphia Photochemical activation of surfaces for attaching biomaterial
US20060041182A1 (en) * 2003-04-16 2006-02-23 Forbes Zachary G Magnetically-controllable delivery system for therapeutic agents
EP2365007B1 (en) 2003-04-16 2015-09-02 The Children's Hospital of Philadelphia Magnetically controllable drug and gene delivery stents
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
WO2005065121A2 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
US20050239091A1 (en) * 2004-04-23 2005-10-27 Collis Matthew P Extraction of nucleic acids using small diameter magnetically-responsive particles
US7842281B2 (en) * 2004-05-10 2010-11-30 The Florida State University Research Foundation Magnetic particle composition for therapeutic hyperthermia
US20060024776A1 (en) * 2004-08-02 2006-02-02 Mcmillian Ray Magnetic particle capture of whole intact organisms from clinical samples
EP1773865A1 (en) * 2004-08-03 2007-04-18 Becton, Dickinson and Company Use of magnetic material to fractionate samples
CN1309779C (zh) * 2004-09-16 2007-04-11 同济大学 一种生物可降解聚合物磁性复合纳米颗粒的制备方法
WO2006050257A2 (en) * 2004-10-29 2006-05-11 Massachusetts Institute Of Tecchnology Detection of ion channel or receptor activity
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US8084275B2 (en) * 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
JP2006242597A (ja) * 2005-02-28 2006-09-14 Fuji Photo Film Co Ltd 磁性体ナノ粒子の凝集・分散制御方法、磁性体ナノ粒子の捕集方法及び磁性体ナノ粒子含有液の処理方法
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren
EP1738774A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
FR2897064B1 (fr) * 2006-02-07 2008-07-25 Centre Nat Rech Scient Preparation de nanoparticules de maghemite enrobees de poly(oxyde d'ethylene).
CA2644694C (en) * 2006-03-10 2014-05-13 Sangeeta N. Bhatia Triggered self-assembly conjugates and nanosystems
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20070258907A1 (en) * 2006-04-24 2007-11-08 Davis Mark E Polymer-coated paramagnetic particles
CN101573141B (zh) 2006-05-15 2016-05-04 麻省理工学院 用于功能性颗粒的聚合物
US20070281034A1 (en) * 2006-05-15 2007-12-06 Kirpotin Dmitri B Magnetic microparticles comprising organic substances
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2069788B1 (en) 2006-10-05 2017-03-01 Massachusetts Institute of Technology Multifunctional encoded particles for high-throughput analysis
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US20090074670A1 (en) 2007-09-07 2009-03-19 Yousef Haik Hyperthermia Therapeutic Agent Delivery System
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8226845B2 (en) * 2008-10-27 2012-07-24 GM Global Technology Operations LLC Iron powder phosphonate coating
US8293213B2 (en) * 2009-03-12 2012-10-23 Palo Alto Research Center Incorporated Method and apparatus for thrombus removal using magnetic particles
AU2010254549B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
GB2472446A (en) * 2009-08-07 2011-02-09 Ct Fuer Angewandte Nanotechnologie Metal oxide particles coated with polyethylene glycol and their synthesis
US9205155B2 (en) * 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
US8565892B2 (en) * 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
KR101616465B1 (ko) 2009-11-02 2016-04-28 펄스 테라퓨틱스, 인코포레이티드 기자성 스테이터 시스템 및 마그네틱 로터의 무선제어 방법
WO2011150258A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2011156432A2 (en) 2010-06-07 2011-12-15 Firefly Bioworks, Inc. Scanning multifunctional particles
CA2819795A1 (en) * 2010-12-15 2012-06-21 General Electric Company Nanoparticle composition and associated methods thereof
US8895068B2 (en) * 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US8889103B2 (en) * 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
WO2012142669A1 (en) * 2011-04-20 2012-10-26 The University Of Sydney A method for the treatment of a solid tumour
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
US9408912B2 (en) 2011-08-10 2016-08-09 Magforce Ag Agglomerating magnetic alkoxysilane-coated nanoparticles
WO2013134633A1 (en) 2012-03-09 2013-09-12 Firefly Bioworks, Inc. Methods and apparatus for classification and quantification of multifunctional objects
US9664667B2 (en) 2012-04-30 2017-05-30 Trustees Of Tufts College Digital quantification of single molecules
US9883878B2 (en) 2012-05-15 2018-02-06 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
DE102014106603A1 (de) 2014-05-12 2015-11-12 Verein zur Förderung von Innovationen durch Forschung, Entwicklung und Technologietransfer e.V. (Verein INNOVENT e.V.) Verfahren und Vorrichtung zur Abreicherung von zirkulierenden Tumorzellen aus einer Zellsuspension
US11046991B2 (en) * 2017-04-12 2021-06-29 Iowa State University Research Foundation, Inc. Rapid preconcentration of viable bacteria using magnetic ionic liquid for PCR amplification and culture-based diagnostics
US11918315B2 (en) 2018-05-03 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles
CN112472824A (zh) * 2019-09-12 2021-03-12 浙江大学医学院附属第四医院 一种特异性靶向对比剂-mr分子影像探针及其制备与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152210A (en) * 1971-08-27 1979-05-01 Beecham Group Limited Biologically active materials attached to a ferromagnetic support
US3917538A (en) * 1973-01-17 1975-11-04 Ferrofluidics Corp Ferrofluid compositions and process of making same
US3933997A (en) * 1974-03-01 1976-01-20 Corning Glass Works Solid phase radioimmunoassay of digoxin
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US3970518A (en) * 1975-07-01 1976-07-20 General Electric Company Magnetic separation of biological particles
GB1582956A (en) * 1976-07-30 1981-01-21 Ici Ltd Composite magnetic particles
US4267234A (en) * 1978-03-17 1981-05-12 California Institute Of Technology Polyglutaraldehyde synthesis and protein bonding substrates
US4230685A (en) * 1979-02-28 1980-10-28 Northwestern University Method of magnetic separation of cells and the like, and microspheres for use therein
US4343901A (en) * 1980-10-22 1982-08-10 Uop Inc. Magnetic support matrix for enzyme immobilization
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4767611A (en) * 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
US5069216A (en) * 1986-07-03 1991-12-03 Advanced Magnetics Inc. Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
JPH04501218A (ja) * 1988-08-04 1992-03-05 アドヴァンスド　マグネティックス　インコーポレーティッド 受容体媒介エンドサイト―シス型ｍｒｉ造影剤
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
WO1992012735A1 (en) * 1991-01-19 1992-08-06 Meito Sangyo Kabushiki Kaisha Composition containing ultrafine particles of magnetic metal oxide
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507197A (ja) * 1996-03-18 2000-06-13 ピルグリム，ヘルベルト Ｒ▲下１▼緩和性を増加した超常磁性体粒子、前記粒子の製造方法およびその使用
JP2005511335A (ja) * 2001-04-13 2005-04-28 コーネル・リサーチ・ファンデーション・インコーポレイテッド 超常磁性ナノ構造材料
JP2006502572A (ja) * 2002-10-09 2006-01-19 フェロファーマ ゲーエムベーハー フォルシュングスラボア 安定化超常磁性粒子
JP2006042621A (ja) * 2004-07-30 2006-02-16 Canon Inc 磁性粒子集合体およびそれを用いた標的核酸の抽出装置および抽出方法
WO2006068294A1 (ja) * 2004-12-24 2006-06-29 Japan Science And Technology Agency 造影剤
JP2006182657A (ja) * 2004-12-24 2006-07-13 Japan Science & Technology Agency 造影剤
US9149545B2 (en) 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
JP2009531296A (ja) * 2006-02-24 2009-09-03 エイティージェン カンパニー リミテッド 造影剤、知能型造影剤、同時診断及び治療のための薬物伝達体及び／又はタンパク質分離用磁性ナノ複合体
JP2010516782A (ja) * 2007-01-26 2010-05-20 ゼネラル・エレクトリック・カンパニイ Ｘ線／コンピュータ断層撮影用のナノ粒子系造影剤及びその製造方法

Also Published As

Publication number Publication date
ATE156706T1 (de) 1997-08-15
US5916539A (en) 1999-06-29
WO1994021240A3 (de) 1994-10-13
EP0689430A1 (de) 1996-01-03
EP0689430B1 (de) 1997-08-13
DE59403734D1 (de) 1997-09-18
WO1994021240A2 (de) 1994-09-29

Similar Documents

Publication Publication Date Title
JPH08508721A (ja) 超常磁性粒子、その製法及びその用途
DE4309333A1 (de) Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben
JP3436760B2 (ja) 超常磁性粒子
US5160725A (en) Magnetic liquid compositions
US6767635B1 (en) Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
JP4079996B2 (ja) Ｒ▲下１▼緩和性を増加した超常磁性体粒子、前記粒子の製造方法およびその使用
Šafařík et al. Magnetic nanoparticles and biosciences
RU2500622C2 (ru) Магнитные преобразователи
Zhu et al. Hydroxyapatite nanoparticles as a novel gene carrier
JP3306810B2 (ja) 超微細結晶酸化鉄磁性粒子とその製造方法並びに医学的診断及び治療における用途
US5547682A (en) Preparation and use of novel injectable RES avoiding inorganic particles for medical application
US20100330159A1 (en) System for transporting active substances in a biological system
JP2007530422A (ja) 磁性ナノ粒子組成物、およびその関連方法
EP1680142A2 (de) Thermosensitive, biokompatible polymerträger mit veränderbarer physikalischer struktur für die therapie, diagnostik und analytik
EP0566590B1 (en) Particulates
DE10020376A1 (de) Dynamische Marker
JPS6187303A (ja) 生物学的磁性液体
JP2005287507A (ja) カチオン性金ナノ粒子及びポリエチレングリコール修飾カチオン性金ナノ粒子並びにそれらの核酸との複合体
KR101079235B1 (ko) 자성 나노복합체, 상기를 포함하는 조영제 조성물 및 약제학적 조성물
Hofmann et al. Nanostructured materials
Lin et al. Complete separation of magnetic nanoparticles via chemical cleavage of dextran by ethylenediamine for intracellular uptake
SUZUKI et al. Enhancement of uptake of magnetoliposomes by magnetic force and hyperthermic effect on tumor
JPH0259428A (ja) 磁性粒子及びその製造法
Wu et al. Hyaluronan-modified Magnetic Hydroxyapatite Nanocrystals for Hyperthermia